The exuberant momentum that defined the Chinese fund market in the first half of the year met a sudden reality check in early July. In just three trading days, the number of 'doubling funds'—those achieving 100% returns—plunged by over 60%, dropping from a peak of 246 to a mere 90. This sharp contraction reflects a broader volatility across the A-share and Hong Kong markets, where investors are rapidly reassessing the sustainability of high-flying tech valuations.
The pivot point arrived on July 2, triggered by whispers of a global compute power 'surplus' and broader tremors in international markets. This sentiment ripple caused the Shanghai Composite and ChiNext indices to tumble significantly, with over 2,000 products seeing single-day losses exceeding 5%. The tech sector, particularly the crowded 'AI-plus' trades involving semiconductors, communications, and electronic components, became the primary epicenter of this sell-off as traders rushed to lock in gains.
However, this retreat from technology does not signal a total market withdrawal, but rather a strategic rotation into undervalued 'laggard' sectors. As tech giants digested their gains, the innovative drug sector, gold, and robotics emerged as contrarian favorites. More than 300 products that had struggled earlier this year have now 'turned green,' reporting positive year-to-date returns fueled by a 5.79% rise in the Shenwan Biomedical Index and an even more robust 11.97% surge in the Hang Seng Innovative Drug Index.
Market analysts suggest that this shift marks a critical transition in investment logic from 'conceptual speculation' to 'earnings verification.' In the first half of the year, growth was driven by the sheer narrative of the AI revolution. Now, as mid-year earnings reports loom, the market is demanding evidence of revenue and profit. Funds that cannot justify their multiples through fundamental growth are being discarded in favor of sectors like biotech, which benefit from domestic pricing reforms and a more reasonable valuation floor.
Despite the dramatic 'thinning out' of top-performing funds, institutional sentiment remains cautiously optimistic about the underlying industrial trends. Many fund managers argue that the current correction is a necessary digestion of 'chips' rather than a trend reversal. While the era of easy, speculative gains in AI may be pausing, the structural transition toward high-quality, innovation-driven growth continues to be the dominant theme for the second half of the year.